Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 3 institutions in 1 country.
Elsa CharignonHospices Civils de Lyon, EA3738-Therapeutic Targeting in Oncology, Université Jean Monnet-Université Claude Bernard Lyon1, 165 Chemin du Grand Revoyet, CEDEX, 69921 Oullins, France.
Mathilde BouchéInstitut de Physique et Chimie des Matériaux de Strasbourg, Université de Strasbourg-CNRS UMR7504, Strasbourg, Bâtiment 69, 23 Rue du Loess, 67200 Strasbourg, France.ORCID 0000-0003-2707-1290
Caroline Clave-DarcissacHospices Civils de Lyon, EA3738-Therapeutic Targeting in Oncology, Université Jean Monnet-Université Claude Bernard Lyon1, 165 Chemin du Grand Revoyet, CEDEX, 69921 Oullins, France.
Georges DahmInstitut de Physique et Chimie des Matériaux de Strasbourg, Université de Strasbourg-CNRS UMR7504, Strasbourg, Bâtiment 69, 23 Rue du Loess, 67200 Strasbourg, France.ORCID 0000-0003-3284-1472
Gabriel IchimCancer Cell Death Laboratory, part of LabEx DEVweCAN, Cancer Initiation and Tumoral Cell Identity Department, Centre de Recherche en Cancérologie de Lyon, 69008 Lyon, France.
Anthony ClotagatideHospices Civils de Lyon, EA3738-Therapeutic Targeting in Oncology, Université Jean Monnet-Université Claude Bernard Lyon1, 165 Chemin du Grand Revoyet, CEDEX, 69921 Oullins, France.
Hichem C MertaniINSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France.ORCID 0000-0002-5958-6662
Philippe TeloukLaboratoire de Géologie de Lyon Terre, Planètes, Université de Lyon, Environnement-ENS-UCBL-CNRS, UMR CNRS 5276 (CNRS, ENS, Université Lyon1), École Normale Supérieure de Lyon, 9 rue du Vercors, CEDEX 07, 69364 Lyon, France.
Julie CaramelINSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France.
Jean-Jacques DiazINSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France.ORCID 0000-0002-7914-4319
Stéphane Bellemin-LaponnazInstitut de Physique et Chimie des Matériaux de Strasbourg, Université de Strasbourg-CNRS UMR7504, Strasbourg, Bâtiment 69, 23 Rue du Loess, 67200 Strasbourg, France.ORCID 0000-0001-9462-5703
Philippe BouvetINSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France.ORCID 0000-0003-4524-2233
Claire BilloteyINSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France.ORCID 0000-0001-7895-6123
Université Claude Bernard Lyon 1 · FRCentre National de la Recherche Scientifique · FRCentre de Recherche en Cancérologie de Lyon · FR
Funding
Idex Université de Strasbourg Programme interdisciplnaireLa ligue contre le cancer CCIR Est
6 · The paper itself
Abstract
We describe here the evaluation of the cytotoxic efficacy of two platinum (II) complexes bearing an N-heterocyclic carbene (NHC) ligand, a pyridine ligand and bromide or iodide ligands on a panel of human metastatic cutaneous melanoma cell lines representing different genetic subsets including BRAF-inhibitor-resistant cell lines, namely A375, SK-MEL-28, MeWo, HMCB, A375-R, SK-MEL-5-R and 501MEL-R. Cisplatin and dacarbazine were also studied for comparison purposes. Remarkably, the iodine-labelled Pt-NHC complex strongly inhibited proliferation of all tested melanoma cells after 1-h exposure, likely due to its rapid uptake by melanoma cells. The mechanism of this inhibitory activity involves the formation of DNA double-strand breaks and apoptosis. Considering the intrinsic chemoresistance of metastatic melanoma cells of current systemic treatments, these findings are promising and could give research opportunities in the future to improve the prognosis of patients suffering from unresectable metastatic melanoma that are not eligible or that do not respond to the most effective drugs available to date, namely BRAF inhibitors and the anti-PD-1 monoclonal antibody (mAb).
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
In Cellulo Evaluation of the Therapeutic Potential of NHC Platinum Compounds in Metastatic Cutaneous Melanoma. · full record | OpenQuestion